Streetbeat News

Products Services

QTTB

Q32 Bio has $107.6M in cash, cash equivalents, and short-term investments as of June 30, 2024. This financial position is expected to support the company through four Phase 2 clinical milestones and into mid-2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:53 am

GNSS

Genasys shares are trading higher following the announcement of a definitive agreement with the Puerto Rico Electric Power Authority to implement its Emergency Warning System across 37 dams.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:52 am

CTXR

The FDA has approved Citius Pharmaceuticals' Lymphir (Denileukin Diftitox-cxdl) for the treatment of relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. This marks the first indication for Lymphir and the first FDA-approved product for Citius Pharmaceuticals.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:50 am

NNVC

NanoViricides has provided an update on its clinical program and strategy in a letter to shareholders. The company highlighted NV-387, an antiviral drug, which it claims could be as revolutionary as antibiotics.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:46 am

DOGEUSD

Dogecoin (DOGE) is attracting bullish predictions from traders who believe it has 'fairly bottomed' and anticipate potential growth, especially with the expected introduction of X payments. Despite a drop in large transaction volumes, daily active addresses have increased. The Dogecoin Foundation highlights the importance of the Cardinals protocol for innovation in the ecosystem.

Portfolio Pulse from Khyathi Dalal

August 08, 2024 | 11:40 am

CARS

Cars.com has revised its FY24 revenue growth projection to 4.5%-5.5%, down from the previous 6.0%-8.0%. Q3 revenues are expected to be $178M-$181M, below the $185.76M estimate. The company cites the CDK cyber incident and slower AccuTrade Connected subscriptions as factors. Adjusted EBITDA margin for Q3 is expected to be 26.5%-28.5%, and for FY24, it remains at 28.0%-30.0%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:40 am

ANEW

ANEW MEDICAL shares are trading higher following the announcement of a new patent issuance (HK1259628) for the treatment of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:40 am

EXAI

RXRX

Recursion Pharmaceuticals (RXRX) and Exscientia (EXAI) have announced a definitive agreement to combine their capabilities to create a leading end-to-end drug discovery platform. The collaboration is expected to yield 10 clinical readouts in the next 18 months, $200 million in milestone payments over 24 months, and potentially $20 billion overall. The companies have $850 million in cash on hand and anticipate $100 million in annual synergies.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:40 am

WIT

Cyble has partnered with Wipro to enhance enterprise cybersecurity risk management using AI-driven threat intelligence solutions. This collaboration combines Cyble's AI systems with Wipro's security expertise.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:38 am

CDT

Conduit Pharmaceuticals shares are trading higher after the company announced it entered into an exclusive license agreement with AstraZeneca to develop AZD1656 and AZD5658.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:38 am